News and Media

More On Colucid

Phase 2b Proof of Concept

Lasmiditan SP-Agreement

IV Lasmiditan Phase 2 Proof of Concept


By the Numbers

More than 36 Million Americans have migraines.

That's 12% of the adult population.

Learn More About the Numbers


About Colucid

CoLucid was founded in 2005 and is developing oral lasmiditan for the acute treatment of migraine headaches in adults and intravenous lasmiditan for the acute treatment of unspecified headache pain in adults in emergency room and other urgent care settings.

Learn More About CoLucid